On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Unveils Full-Spectrum CBD Oil

  • SPRWF launches Pūr Dew, an exclusive, full-spectrum CBD oil available under company’s wellness-focused brand, Blissco
  • New product part of company’s strategic entry into one of the fastest-growing product segments
  • Initially available in British Columbia, new product expected in other provinces in coming months

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of cannabis companies, has launched its newest product – Pūr Dew, an exclusive, full-spectrum CBD oil available under the company’s wellness-focused brand, Blissco (http://ibn.fm/8DYnc). The product marks a milestone for Supreme Cannabis Company as it enters the CBD market; current SPRWF products include dry flower from SPRWF subsidiary 7ACRES and high-THC cannabis oil from Khalifa Kush Enterprises Canada.

“We are excited to expand our product offering to include CBD, arguably one of the fastest-growing product segments on the market,” Supreme Cannabis Company CEO Navdeep Dhaliwal stated in a news release. “As Blissco’s first CBD oil, Pūr Dew offers consumers full-spectrum CBD and USDA-certified-organic MCT coconut oil. Our team worked incredibly hard to provide consumers with a product that retains the benefits of the plant and the natural terpenes. Pūr Dew can be taken directly or mixes well into beverages, such as smoothies. We are excited for consumers to try Pūr Dew.”

Made from pure-CBD cannabis oil and USDA-certified-organic MCT coconut oil, Pūr Dew is manufactured at the company’s facility in Langley, British Columbia. Through careful formulation and extraction, Blissco has retained delicate terpenes, giving the new CBD-oil product a gentle smell of clove, citrus and pine. Available initially in British Columbia, Pūr Dew will be available in other Canadian provinces throughout the next year.

In addition to prioritizing quality and creating a high-end product formulation, Supreme Cannabis and the Blissco brand have made sustainability a priority as well. Blissco sources packaging that is as environmentally friendly as possible. With that in mind, Pūr Dew comes in recyclable glass bottles with its outer cardboard packaging made from 100% post-consumer wastepaper.

Since 2014, Supreme Cannabis Company has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies by effectively deploying capital, with an emphasis on disciplined growth and high-quality products. Noting that the CBD market for legal cannabis sales in Canada alone is expected to reach $4.7 billion by 2023, with sales in the United States projected to top $24 billion by that time (http://ibn.fm/99AHO), the company is strategically entering a lucrative market with a high-quality product offering.

Supreme Cannabis Company’s portfolio includes 7ACRES, its wholly owned subsidiary and multi-award-winning brand; Blissco, a wellness cannabis brand and a multi-licensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a plant genetics and cultivation IP company; Medigrow Lesotho, a cannabis oil producer located in Southern Africa; Supreme Heights, an investment platform focused on CBD brands in the United Kingdom and Europe; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

From Our Blog

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

September 25, 2020

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, […]

Rotate your device 90° to view site.